1. Home
  2. GMAB
  3. GMAB News

Latest Genmab A/S ADS (GMAB) News on December 22, 2024

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
GMAB

GlobeNewswire

11 days ago

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
GMAB

Business Wire

12 days ago

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
GMAB

GlobeNewswire

12 days ago

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

GMAB

MT Newswires

13 days ago

Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial

Exploring None's High Growth Tech Stocks With Strong Potential
GMAB

Simply Wall St.

13 days ago

Exploring None's High Growth Tech Stocks With Strong Potential

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
GMAB

Business Wire

14 days ago

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
GMAB

GlobeNewswire

14 days ago

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Capital Increase in Genmab as a Result of Employee Warrant Exercise
GMAB

GlobeNewswire

18 days ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
GMAB

GlobeNewswire

19 days ago

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Why Is Genmab A/S (GMAB) Among the Best High Growth Healthcare Stocks to Invest In Now?
GMAB

Insider Monkey

19 days ago

Why Is Genmab A/S (GMAB) Among the Best High Growth Healthcare Stocks to Invest In Now?

Why Is Genmab A/S (GMAB) Among the Worst Performing Healthcare Stocks in 2024?
GMAB

Insider Monkey

25 days ago

Why Is Genmab A/S (GMAB) Among the Worst Performing Healthcare Stocks in 2024?

Genmab to Present at Citi’s Global Healthcare Conference
GMAB

GlobeNewswire

a month ago

Genmab to Present at Citi’s Global Healthcare Conference

Why Is Genmab A/S (GMAB) Among the Worst Performing Biotech Stocks in 2024?
GMAB

Insider Monkey

a month ago

Why Is Genmab A/S (GMAB) Among the Worst Performing Biotech Stocks in 2024?

Grant of Restricted Stock Units and Warrants to Employees in Genmab
GMAB

GlobeNewswire

a month ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now
GMAB

Insider Monkey

a month ago

Genmab A/S (GMAB): Among 12 High Growth Large Cap Stocks to Buy Now

High Growth Tech Stocks To Watch In November 2024
GMAB

Simply Wall St.

a month ago

High Growth Tech Stocks To Watch In November 2024

Genmab AS (GMAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Pipeline ...
GMAB

GuruFocus.com

a month ago

Genmab AS (GMAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Pipeline ...

GMAB

MT Newswires

a month ago

Genmab Shares Fall After Reporting Q3 Results

Genmab Announces Financial Results for the First Nine Months of 2024
GMAB

GlobeNewswire

2 months ago

Genmab Announces Financial Results for the First Nine Months of 2024

Genmab to Present at Jefferies London Healthcare Conference
GMAB

GlobeNewswire

2 months ago

Genmab to Present at Jefferies London Healthcare Conference

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
GMAB

Business Wire

2 months ago

Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting

Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics
GMAB

Insider Monkey

2 months ago

Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics

Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?
GMAB

Zacks

2 months ago

Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?

Is Genmab (GMAB) Stock Undervalued Right Now?
GMAB

Zacks

2 months ago

Is Genmab (GMAB) Stock Undervalued Right Now?

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
GMAB

GlobeNewswire

2 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024

Genmab A/S (GMAB): Among The Stocks With Biggest Upside Potential According to Hedge Funds
GMAB

Insider Monkey

2 months ago

Genmab A/S (GMAB): Among The Stocks With Biggest Upside Potential According to Hedge Funds

GMAB or INCY: Which Is the Better Value Stock Right Now?
GMAB

Zacks

2 months ago

GMAB or INCY: Which Is the Better Value Stock Right Now?

Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround
GMAB

Zacks

2 months ago

Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround

Major Shareholder Announcement
GMAB

GlobeNewswire

3 months ago

Major Shareholder Announcement

Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?
GMAB

Insider Monkey

3 months ago

Is Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?

Grant of Restricted Stock Units and Warrants to Employees in Genmab
GMAB

GlobeNewswire

3 months ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GMAB

MT Newswires

3 months ago

Genmab Reports 'Encouraging' Data From Phase 1/2 Study of Investigational Ovarian Cancer Drug

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
GMAB

Business Wire

3 months ago

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

Capital Increase in Genmab as a Result of Employee Warrant Exercise
GMAB

GlobeNewswire

3 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GMAB

MT Newswires

3 months ago

Truist Lowers Price Target on Genmab to $50 From $53, Maintains Buy Rating

Genmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers
GMAB

Insider Monkey

4 months ago

Genmab A/S (GMAB): One of the Best Affordable Stocks Under $40 According to Short Sellers

GMAB

MT Newswires

4 months ago

HOOKIPA Pharma Names Julie O'Neill Nonexecutive Chair

Top High Growth Tech Stocks To Watch In August 2024
GMAB

Simply Wall St.

4 months ago

Top High Growth Tech Stocks To Watch In August 2024

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
GMAB

GlobeNewswire

4 months ago

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use
GMAB

Zacks

4 months ago

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use

GMAB

MT Newswires

4 months ago

Genmab, AbbVie Get Conditional European Commission Approval for Lymphoma Treatment

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
GMAB

Business Wire

4 months ago

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
GMAB

GlobeNewswire

4 months ago

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

GMAB

MT Newswires

4 months ago

Genmab COO Anthony Mancini Departs; Firm Names New CTO, CCO

Genmab Announces Changes to its Executive Committee
GMAB

Business Wire

4 months ago

Genmab Announces Changes to its Executive Committee

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GMAB

GlobeNewswire

4 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Capital Increase in Genmab as a Result of Employee Warrant Exercise
GMAB

GlobeNewswire

4 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GMAB

MT Newswires

4 months ago

Genmab's Interim Q2 Earnings, Revenue Climb; Increases 2024 Revenue Guidance

Genmab Announces Financial Results for the First Half of 2024
GMAB

GlobeNewswire

4 months ago

Genmab Announces Financial Results for the First Half of 2024

Genmab Updates 2024 Financial Guidance
GMAB

GlobeNewswire

4 months ago

Genmab Updates 2024 Financial Guidance

BioNTech exits PD-L1 development with Genmab as Q2 revenues drop
GMAB

Pharmaceutical Technology

5 months ago

BioNTech exits PD-L1 development with Genmab as Q2 revenues drop

BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls
GMAB

Investopedia

5 months ago

BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls

Genmab Takes Full Control of Acasunlimab Development Program
GMAB

GlobeNewswire

5 months ago

Genmab Takes Full Control of Acasunlimab Development Program

Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet
GMAB

Zacks

5 months ago

Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet

Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat
GMAB

Zacks

5 months ago

Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat

All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy
GMAB

Zacks

5 months ago

All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy

GMAB vs. CSLLY: Which Stock Is the Better Value Option?
GMAB

Zacks

5 months ago

GMAB vs. CSLLY: Which Stock Is the Better Value Option?

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
GMAB

GlobeNewswire

5 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024

GMAB

MT Newswires

5 months ago

RBC Upgrades Genmab to Outperform From Sector Perform, Keeps Price Target at DKK2,400

GMAB or TECH: Which Is the Better Value Stock Right Now?
GMAB

Zacks

5 months ago

GMAB or TECH: Which Is the Better Value Stock Right Now?

GMAB vs. TECH: Which Stock Is the Better Value Option?
GMAB

Zacks

5 months ago

GMAB vs. TECH: Which Stock Is the Better Value Option?

AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
GMAB

Zacks

6 months ago

AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use

GMAB

MT Newswires

6 months ago

AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
GMAB

Business Wire

6 months ago

Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma

Completion of Share Buy-back Program
GMAB

GlobeNewswire

6 months ago

Completion of Share Buy-back Program

FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
GMAB

Zacks

6 months ago

FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma

GMAB

MT Newswires

6 months ago

BTIG Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating

GMAB

MT Newswires

6 months ago

Genmab Gets FDA Approval for Follicular Lymphoma Treatment

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
GMAB

Business Wire

6 months ago

EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

6 months ago

Transactions in Connection with Share Buy-back Program

Capital Increase in Genmab as a Result of Employee Warrant Exercise
GMAB

GlobeNewswire

6 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

6 months ago

Transactions in Connection with Share Buy-back Program

Grant of Restricted Stock Units and Warrants to Employees in Genmab
GMAB

GlobeNewswire

6 months ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GMAB

GlobeNewswire

6 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
GMAB

PR Newswire

6 months ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
GMAB

Business Wire

6 months ago

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

New Zealand scraps plan to tax livestock burps, farts
GMAB

AFP

6 months ago

New Zealand scraps plan to tax livestock burps, farts

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility
GMAB

The Wall Street Journal

6 months ago

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

GMAB

Business Wire

6 months ago

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

UK Unemployment Rises in Sign Inflationary Pressures Cool
GMAB

Bloomberg

6 months ago

UK Unemployment Rises in Sign Inflationary Pressures Cool

Insider-Owned Growth Companies On The Chinese Exchange In June 2024
GMAB

Simply Wall St.

6 months ago

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

Here's Why New Toyo International Holdings (SGX:N08) Has Caught The Eye Of Investors
GMAB

Simply Wall St.

6 months ago

Here's Why New Toyo International Holdings (SGX:N08) Has Caught The Eye Of Investors

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

6 months ago

Transactions in Connection with Share Buy-back Program

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GMAB

Business Wire

6 months ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GMAB

GlobeNewswire

6 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23
GMAB

GlobeNewswire

6 months ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
GMAB

Simply Wall St.

6 months ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May
GMAB

Reuters

6 months ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
GMAB

AFP

6 months ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share
GMAB

GlobeNewswire

6 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Enduring role of 'treasuring the past' hailed
GMAB

PR Newswire

6 months ago

Enduring role of 'treasuring the past' hailed

Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
GMAB

GlobeNewswire

7 months ago

Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference

GMAB

MT Newswires

7 months ago

Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating

GMAB

MT Newswires

7 months ago

Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

7 months ago

Transactions in Connection with Share Buy-back Program

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
GMAB

Business Wire

7 months ago

Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Genmab and BioNTech report data from Phase II GCT1046-04 trial for mNSCLC
GMAB

Clinical Trials Arena

7 months ago

Genmab and BioNTech report data from Phase II GCT1046-04 trial for mNSCLC

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
GMAB

Business Wire

7 months ago

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
GMAB

GlobeNewswire

7 months ago

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
GMAB

Business Wire

7 months ago

Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

Share on Social Networks: